The efficacy of etiotropic therapy for a new coronavirus infection with Areplevir (favipiravir), depending on the time of initiation of treatment (clinical observation)

• Larisa A. Balykova
• Vera F. Pavelkina
• Nina P. Ampleeva
• Natalia M. Selezneva

Abstract

The current millennium has been marked by the emergence of 3 epidemics of coronavirus infection: severe acute respiratory syndrome (SARS, SARS-CoV or atypical pneumonia), Middle East respiratory syndrome (MERS-CoV) and, over the past year, severe acute respiratory syndrome caused by the new coronavirus infection (SARS). CoV2, COVID-19). COVID-19 turned out to be the most common, far ahead of other epidemics in terms of the number of infected and mortality. The use of a vaccine will undoubtedly become the most important method of combating a new pandemic, but its creation is associated with certain difficulties, both in terms of lack of time and due to the high rate of spontaneous mutations inherent in all RNA viruses and coronavirus in particular. In this regard, the development of effective treatment regimens aimed at inhibiting the virus, suppressing the secondary effects of the cytokine storm and/or modulating the body's immune system, as well as blocking some specific links in the pathogenesis of COVID 19 (for example, hypercoagulation) is a priority area of modern medicine. The article describes clinical observations demonstrating an improvement in the clinical status of patients while using the drug Areplivir (favipiravir), which blocks viral replication and has proven its efficacy in controlled trials.

Keywords:COVID-19, favipiravir, Areplivir, clinical case

References

1. de Wit E., van Doremalen N., Falzarano D., Munster V.J. SARS and MERS: recent insights into emerging coronaviruses. Nat Rev Microbiol. 2016; 14 (8): 523–34. DOI: https://doi.org/10.1038/nrmicro.2016.81

2. Yang L., Tian D., Liu W. Strategies for vaccine development of COVID-19. Sheng Wu Gong Cheng Xue Bao. 2020; 36 (4): 593–604. DOI: https://doi.org/10.13345/j.cjb.200094 (in Chinese)

3. McCreary E.K., Pogue J.M. Coronavirus disease 2019 treatment: a review of early and emerging options. Open Forum Infect Dis. 2020; 7 (4): ofaa105. DOI: https://doi.org/10.1093/ofid/ofaa105

4. Giovane R.A., Rezai S., Cleland E., Henderson C.E. Current pharmacological modalities for management of novel coronavirus disease 2019 (COVID-19) and the rationale for their utilization: a review. Rev Med Virol. 2020; e2136. DOI: https://doi.org/10.1002/rmv.2136

5. Mitjà O., Clotet B. Use of antiviral drugs to reduce COVID-19 transmission. Lancet Glob Health. 2020; 8: e639–e640. DOI: https://doi.org/10.1016/S2214-109X(20)30114-5

6. Wu R., Wang L., Kuo H.D., et al. An Update on Current Therapeutic Drugs Treating COVID-19. Curr Pharmacol Rep. 2020; 6: 56–70. DOI: https://doi.org/10.1007/s40495-020-00216-7

7. Esposito S., Noviello S., Pagliano P. Update on treatment of COVID-19: ongoing studies between promising and disappointing results. Infez Med. 2020; 28 (2): 198–211.

8. Bhimraj A., Morgan R.L., Shumaker A.H., et al. Infectious Diseases Society of America Guidelines on the Treatment and Management of Patients with COVID-19 [published online ahead of print, 2020 Apr 27]. Clin Infect Dis. 2020; ciaa478. DOI: https://doi.org/10.1093/cid/ciaa478

9. Kalil A.C. Treating COVID-19-off-label drug use, compassionate use, and Randomized clinical trials during pandemics. JAMA. 2020. 323 (19): 1897–8. DOI: https://doi.org/10.1001/jama.2020.4742

10. Wang Y., Zhang D., Du G., et al. Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial [published correction appears in Lancet. 2020; 395 (10238): 1694]. Lancet. 2020; 395 (10236): 1569–78. DOI: https://doi.org/10.1016/S0140-6736(20)31022-9

11. Cao B., Wang Y., Wen D., et al. A Trial of lopinavir-ritonavir in adults hospitalized with severe Covid-19. N Engl J Med. 2020; 382 (19): 1787–99. DOI: https://doi.org/10.1056/NEJMoa2001282

12. Zhu Z., Lu Z., Xu T., et al. Arbidol monotherapy is superior to lopinavir/ritonavir in treating COVID-19. J Infect. 2020; 81 (1): e21–e23. DOI: https://doi.org/10.1016/j.jinf.2020.03.060

13. Hung I.F., Lung K.C., Tso E.Y., et al. Triple combination of interferon beta-1b, lopinavirritonavir, and ribavirin in the treatment of patient s admitted to hospital with COVID-19: an open-label, randomised, phase 2 trial. Lancet. 2020; 395 (10238): 1695–1704. DOI: https://doi.org/10.1016/S0140-6736(20)31042-4

14. Zhou Q., Chen V., Shannon C.P., et al. Interferon-a2b Treatment for COVID-19. Front Immunol. 2020; 11: 1061. DOI: https://doi.org/10.3389/fimmu.2020.01061

15. Ippolito M., Giarratano A., Einav S. A systematic review onthe efficacy and safety of chloro-quine for the treatment ofCOVID-19. J Crit Care. 2020; 57: 279-83. DOI: https://doi.org/10.1016/j.jcrc.2020.03.005

16. Chen C., et al. Favipiravir versus arbidol for COVID-19: arandomized clinical trial. medRxiv. 2020: 2020.03.17.20037432. DOI: https://doi.org/10.1101/2020.03.17.20037432

17. Cai Q., Yang M., Liu D., et al. Experimental treatment withfavipiravir for COVID-19: an open-label control study. Engineering. 2020. DOI: https://doi.org/10.1016/j.eng2020.03.007

18. Временные методические рекомендации (ВМР) Минздрава России «Профилактика, диагностика и лечение новой коронавирусной инфекции (COVID-19)», версия 7 от 03.06.2020. [Temporary guidelines of the Ministry of Health of the Russian Federation "Prevention, diagnosis and treatment of new coronavirus infection (COVID-19)”, version from June 3, 2020. (in Russian)]

19. COVID-19 Therapeutic trial synopsis, draft February 18, 2020. https://www.who.int/blueprint/priority-diseases/key-action/COVID-19_Treatment_Trial_Design_Master_Protocol_syn-opsis_Final_18022020.pdf

20. Inui S., Fujikawa A., Jitsu M., et al. Chest CT findings in cases from the cruise ship «Dia-mond Princess» with Coronavirus Disease 2019 (COVID-19). Radiology: Cardiothoracic Imaging. 2020; 2: e200110. DOI: https://doi.org/10.1148/ryct.2020200110

21. Chen J., Qi T., Liu L., et al. Clinical progression of patients with COVID-19 in Shanghai, China. J Infect. 2020; 80 (5): e1-e6. DOI: https://doi.org/10.1016/jjinf.2020.03.004

22. Wu J., Li W., Shi X., et al. Early antiviral treatment contributes to alleviate the severity and improve the prognosis of patients with novel coronavirus disease (COVID-19). J Intern Med. 2020; 288 (1): 128-8. DOI: https://doi.org/10.1111/joim.13063

23. Письмо Федеральной службы по надзору в сфере защиты прав потребителей и благополучия человека от 13.06.2019 № 2/8515-2019-32 «Об итогах эпидемического сезона по гриппу и ОРВИ 2018-2019 гг. и задачах на 2019-2020 гг.» [Letter of the Federal Service for Surveillance on Consumer Rights Protection and Human Welfare dated June 13, 2019 No. 2/8515-2019-32 ”On the results of the epidemic season for influenza and SARS in 2018-2019 and tasks for 2019-2020”. (in Russian)]

24. Shiraki K., Daikoku T. Favipiravir, an anti-influenza drug against life-threatening RNA virus infections. Pharmacol Ther. 2020; 209: 107512. DOI: 10.1016/j.pharmthera.2020.107512

25. Preliminary report of the favipiravir observational study in Japan - 2020/5/15-Fa-vipiravir Observational Study Group. Available from: http://www.kansensho.or.jp/uploads/files/topics/2019ncov/covid19_casereport_en_200529.pdf

All articles in our journal are distributed under the Creative Commons Attribution 4.0 International License (CC BY 4.0 license)